Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978694 | 0.89 | KDM2B (0.52) | P2RX7KDM2BALDH1A1HRH1HRH3 | |
| SCHEMBL4976392 | 0.85 | MEN1 (0.49) | P2RX7KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4977982 | 0.85 | KDM4E (0.53) | P2RX7KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4976500 | 0.84 | P2RX7 (0.42) | P2RX7KDM2BPDE2AMEN1KMT2A | |
| SCHEMBL4974572 | 0.84 | P2RX7 (0.43) | P2RX7ALDH1A1HRH1HRH3KCNK3 | |
| SCHEMBL4978484 | 0.83 | KDM2B (0.50) | P2RX7KDM2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL4980177 | 0.83 | KCNK3 (0.49) | P2RX7KDM2BKDM4EALDH1A1HRH1 | |
| SCHEMBL4976149 | 0.83 | HPGD (0.46) | P2RX7KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4976388 | 0.82 | KDM2B (0.53) | P2RX7KDM2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL4976310 | 0.80 | TSHR (0.45) | KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | P2RX7 38/4885KDM2B 1937/4885PDE2A 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.